Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma

INTRODUCTION: Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by its drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest and increases the sensitivity of glioma to TMZ. Ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Nanomedicine
Main Authors: Shi, Hui, Sun, Shuo, Xu, Haoyue, Zhao, Zongren, Han, Zhengzhong, Jia, Jun, Wu, Dongmei, Lu, Jun, Liu, Hongmei, Yu, Rutong
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229804/
https://ncbi.nlm.nih.gov/pubmed/32494134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S243878
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados